Drugs / FMC-376
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06244771 | Feb 2024 → Oct 2027 expected | colorectal cancer, malignant pancreatic neoplasm, metastatic malignant neoplasm, non-small cell lung carcinoma | Frontier Medicines Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-22 | Frontier Medicines Corporation | Results Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets frontiermeds.com ↗
FMC-376 demonstrated robust anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream pathways compared to sotorasib |
| 2024-04-09 | Frontier Medicines Corporation | Results Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting frontiermeds.com ↗
The new findings demonstrate FMC-376’s potential to overcome known mechanisms of innate and acquired resistance and in a CNS model of metastasis as a monotherapy and increase the efficacy of PD-1 immunotherapy in combination. |
| 2023-04-16 | Frontier Medicines Corporation | Results Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting frontiermeds.com ↗
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today unveiled new preclinical data on its KRAS G12C inhibitor, FMC-376, demonstrating its uniquely differentiated mode of action. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMC-376 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06244771 ↗ |
| Route | Oral | “Oral Capsule Daily” NCT06244771 ↗ |